Related Experiment Video
Updated: Dec 10, 2025
Comparing the Effects of Electronic Cigarette Vapor and Cigarette Smoke in a Novel In Vivo Exposure System
Published on: May 24, 2017
Modern sulphonylureas and cardiovascular adverse effects: Will CAROLINA put an end to the controversy?
Mathew John1, Sanjay Kalra2, Tiny Nair3
1Department of Endocrinology and Diabetes, Providence Endocrine and Diabetes Specialty Centre, Trivandrum, Kerala, 695011, India.
Abstract:
Sulphonylureas (SU) form an important role in management of people with type 2 diabetes. This safety history of SU was tainted for various reasons, the predominant one being lack of demonstration of cardiovascular safety. Since its introduction, SU's have never been subjected to a formal study for its cardiovascular safety. The cardiovascular safety of SUs was derived from small, inadequately powered randomised controlled trials (RCT) and observational studies. CAROLINA (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) trial planned as a cardiovascular outcome trial randomised people with type 2 diabetes and high cardiovascular risk to Linagliptin and Glimepiride. This opinion paper outlines the salient features of this landmark trial and its implications in general cardiology practice.
